Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Smallpox Sequela FDA Draft Guidance Recommends Data Collection Systems

Executive Summary

An FDA draft guidance on developing drugs to treat complications associated with smallpox vaccination lists data collection recommendations for pre-terrorism events, post-terrorism events and post-approval

Related Content

Wyeth Dryvax Smallpox Vaccine Approved For 100-Dose Kit, 30-Day Expiration
Smallpox Vaccine Adverse Event Treatment Will Be Made Under CDC Contract
Anthrax Post-Exposure Drugs Need Extensive Marketing History – Draft Guidance



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts